Fiducial Markers Market To Reach A Valuation Of US$ 295.6 Million By 2032

Fiducial Markers Market

The study predicts that the Fiducial Markers Market will advance significantly and see positive annual growth in 2021. Fact.MR predicts that growth will be positive from 2021 to 2031, with a CAGR of above 4%.

The industry is anticipated to benefit from the increased focus on cutting-edge cancer research and treatment. According to the International Agency for Research on Cancer (IARC), approximately 12% of men and 9% of women worldwide are estimated to develop cancer at some point in their lifetime. Furthermore, more than 50 million people are still alive five years after receiving a previous diagnosis. As a result, efforts to support cancer research have increased, creating favourable conditions for the proliferation of fiducial markers.

Fiducial markers have become the industry standard for image-guided radiotherapy throughout time, inspiring manufacturers to provide fresh goods on the market. The potential for fiducial markers is set to grow in the coming years as governments in emerging nations step up efforts to expand healthcare access. According to studies, between 40 to 62% of patients might anticipate to benefit from radiation. Demand is expected to continue to be quite strong, particularly among elderly patients with solid tumors.

The Global Taskforce on Radiotherapy for Cancer Control (GTFRCC) discovered that by 2035, nearly 12 million cancer patients would benefit from radiotherapy, with the potential to save 950,000 lives and help control cancer for 2.5 million people globally.

“Cutting-edge technology penetration has led to prolific advancements in fiducial markers, with manufacturers effectively leveraging advancements such as precision-based imaging to assist healthcare providers in achieving higher accuracy in oncology treatment procedures,” says the Fact.MR analyst.

Download a Sample Copy of This Report:

Key Takeaways from Fact.MR’s Fiducial Markers Study

  • Pure gold fiducial markers are expected to remain lucrative, attributed to extensive adoption in treating prostate cancer
  • Photon therapy to emerge as the primary modality, owing to greater effectiveness in inhibiting cancer cells multiplication
  • By disease site, prostate cancer treatment remains principal application area, lung cancer treatment to proliferate
  • Radiotherapy centers to account for the majority of fiducial markers deployment, attributed to numerous coalitions with agencies to foster cancer research
  • U.S. to account for a lucrative market fiducial marker share, with an increase in the number of oncology treatment centers
  • Growing incidences of breast cancer to fuel fiducial marker sales across Germany
  • U.K. to witness steady annual expansion amid rapid advancements in image guide therapeutic procedures
  • High geriatric population pool and the resultant increase in cancer treatment to augment sales across IndiaChinaJapan and South Korea respectively

Competitive Landscape

Key fiducial markers manufacturers profiled in Fact.MR’s report include Eckert & Zieglar BEBIG, Innovative Oncology Solutions, Boston Scientific, IBA, Best Medical International Inc., IZI Medical Products, Carbon Medical Technologies, CIVCO, AlphaXRT, Nanovi A/S and Stellar Medical. Players are attempting to establish a firm footing by diversifying existing portfolios through new product launches and other inorganic strategies.

In 2018, Boston Scientific introduced the LumiCoil Platinum Fiducial Markers featuring platinum construction designed for clear visibility in CT, X-Ray, EUS, CBCT and MRI procedures. This device has immensely helped achieve precision in radiation delivery, leaving healthy tissues undamaged.

In March 2020, Nanovi A/S earned the CE mark for its BioXmark® novel liquid fiducial marker intended for marking soft body tissues for enhanced visibility on medical imaging, thus facilitating high precision radiation therapy. It consists of an adhesive-like iodine-based soft marker for adaptability to surrounding tissues, positional stability and visibility on relevant imaging modalities.

More Valuable Insights on Fiducial Markers Market

In the latest report by Fact.MR, we offer an unbiased analysis of the global fiducial markers market, providing historical data for the period of 2016-2020 and forecast statistics for the period of 2021-2031. In order to understand the global market potential, its growth, and scope, the market is segmented on the basis of product (metal-based, polymer-based, and others) and cancer type (lung cancer, breast cancer, prostate cancer, and others), across seven major regions of the world (North AmericaLatin AmericaEuropeEast AsiaSouth Asia, Oceania, and MEA).

Get Customization on this Report for Specific Research Solutions:

Segmentation of Fiducial Marker Industry Research

  • By Product Type :
    • Polymer-based Markers
    • Metal-based Markers
    • Pure Gold Markers
    • Liquid-based Markers
  • By Modality :
    • Photon Therapy
    • Proton Therapy
    • Tomotherapy
    • Cyberknife
  • By Disease Site :
    • Head & Neck
    • Breast
    • Lung
    • Abdomen
    • Prostate
    • Kidney
    • Cervix or Other Gynaecologic Organs
  • By End User :
    • Hospitals
    • Cancer Research Institutes
    • Radiotherapy Centers
  • By Region :
    • North America
    • Latin America
    • Europe
    • East Asia
    • South Asia & ASEAN
    • Oceania
    • MEA

Key Questions Covered in the Report:

  • Which segment accounted for the largest fiducial markers market share?
  • What are the factors driving the fiducial markers market?
  • Are Investments by Governments Fuelling Sales of Fiducial Markers?
  • What are the Key Challenges Faced by Fiducial Marker Manufactures?
  • Why are Fiducial Marker Manufacturers Eyeing the United States?

US Sales Office :
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583